Related Experiment Video

Updated: Aug 15, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Farnesyltransferase inhibitors in breast cancer therapy

Grace K Dy1, Alex A Adjei

  • 1Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. adjei.alex@mayo.edu

Cancer Investigation
|November 22, 2002
PubMed

Insights

Farnesyltransferase inhibitors (FTIs) show promise in treating breast cancer by blocking Ras signaling pathways. Their effectiveness extends beyond tumors with Ras mutations, indicating broader therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Farnesyltransferase inhibitors (FTIs) were developed to inhibit Ras protein's membrane attachment.
  • Ras-mediated signaling pathways are crucial for tumor proliferation and survival.
  • While Ras mutations are infrequent in breast cancer, aberrant signaling pathways can still activate wild-type Ras.

Purpose of the Study:

  • To review current data on the application of FTIs in breast cancer treatment.
  • To explore the mechanisms underlying FTI efficacy in breast cancer.
  • To investigate the role of alternative protein targets in FTI-mediated antitumor effects.

Main Methods:

  • Literature review of preclinical and clinical studies on FTIs in breast cancer.
  • Analysis of data regarding Ras signaling pathways and FTI mechanisms of action.
  • Examination of studies investigating FTI efficacy across different breast cancer subtypes and mutational statuses.

Main Results:

  • FTIs demonstrate antitumor activity in breast cancer models.
  • Efficacy of FTIs is observed irrespective of Ras mutational status.
  • Emerging evidence suggests FTIs target proteins beyond Ras, contributing to their therapeutic effects.

Conclusions:

  • FTIs represent a potential therapeutic strategy for breast cancer.
  • Further research is warranted to fully elucidate the mechanisms of action and identify novel targets for FTIs.
  • FTIs may offer a valuable treatment option, particularly in tumors with activated Ras signaling through various pathways.

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...